Natco Pharma USA Successfully Integrates DASH Pharmaceuticals for Strategic Expansion

04 Jan, 2024

Natco Pharma Limited, an India-based pharmaceutical company with a focus on research and development (R&D), has officially announced the successful transition of DASH Pharmaceuticals into Natco Pharma USA, its U.S. subsidiary.

This strategic move, effective from January 2, signifies the integration of DASH's generic pharmaceutical products under the Natco Pharma USA label, maintaining continuity with existing National Drug Code (NDC) numbers.

Heading Natco Pharma USA is Subba Rao Mente, serving as Chief Executive Officer, with Julie Trendowicz and Nick DiMaio retaining their roles as the former Executive Vice President and President of DASH, respectively, now operating under Natco Pharma USA.

This transition marks a significant step for Natco Pharma, providing a strategic foothold in the United States. Subba Rao Mente emphasized the importance of direct connectivity with U.S. customers, reinforcing their commitment to the American pharmaceutical landscape.

Natco Pharma's presence in the U.S. dates back to 2007, marked by collaborations and licensing partnerships with major generic pharmaceutical companies. The company's track record includes pioneering first-to-market generics and complex formulations, solidifying its reputation in the U.S. generic pharmaceutical industry. Notable products include Lenalidomide Capsules, Glatiramer Acetate Pre-Filled Syringes, Liposomal Doxorubicin Vials, Oseltamivir Phosphate Capsules, Lanthanum Carbonate Chewable Tablets, Everolimus Tablets, and Lapatinib Tablets.

With the establishment of Natco Pharma USA, the company aims to further enhance accessibility and affordability of its generic products, fostering continued growth and expansion in the U.S. market.

Related News

Interview